Therapeutic vaccine based on a VB6: Began a 10-patient Phase I trial

The Immune Response Corp. (IMNR), Carlsbad, Calif. Product: Therapeutic vaccine based on a VB6.2/6.5 T cell receptor peptide Indication: Multiple sclerosis Status: Began a 10-patient Phase I trial to ...